Back To Schedule
Monday, June 15 • 3:30pm - 4:30pm
#132 SL: Benchmarking and Identifying Opportunities to Improve Intentional Dose Non-Adherence in Clinical Trials

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Component Type: Forum
Level: Intermediate
CE: ACPE 1.00 Knowledge UAN: 0286-0000-20-561-L04-P; CME 1.00; IACET 1.00; RN 1.00

The results of a groundbreaking study quantifying intentional dose non-adherence are presented followed by a discussion among a panel of clinical and regulatory professionals on the implications of the findings.

Learning Objectives

Quantify intentional dose non-adherence rates in clinical trials; Identify factors associated with, and predictive of intentional non-adherence; Discuss policies and solutions to address and reduce intentional non-adherence.


Kenneth A. Getz, MBA


Quantifying the Magnitude of Intentional Dose Non Adherence
Kenneth A. Getz, MBA

Accounting For and Managing Dose Non-Adherence in Clinical Trials
Marlen Rattiner, MA

avatar for Kenneth Getz

Kenneth Getz

Director, Research Professor, Tufts Center For the Study of Drug Development
Kenneth A. Getz, MBA, is the Deputy Director and Professor at the Tufts Center for the Study of Drug Development, Tufts University School of Medicine, where he directs research programs on drug development management strategy and practice. He is also the Founding Chair of the Center... Read More →

Marlen Rattiner

Vice President, Product Management, AiCure

Monday June 15, 2020 3:30pm - 4:30pm EDT
TBD Virtual Event Horsham, PA 19044
  08: R-D Quality-Compliance, Forum